S. 4120 — Childhood Cancer STAR Reauthorization Act

[117th Congress Public Law 350]
[From the U.S. Government Publishing Office]



[[Page 6261]]

     CHILDHOOD CANCER SURVIVORSHIP, TREATMENT, ACCESS, AND RESEARCH 
                       REAUTHORIZATION ACT OF 2022

[[Page 136 STAT. 6262]]

Public Law 117-350
117th Congress

                                 An Act


 
 To maximize discovery, and accelerate development and availability, of 
          promising childhood cancer treatments, and for other 
             purposes. <<NOTE: Jan. 5, 2023 -  [S. 4120]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled, <<NOTE: Childhood Cancer 
Survivorship, Treatment, Access, and Research Reauthorization Act of 
2022.>> 
SECTION 1. <<NOTE: 42 USC 201 note.>> SHORT TITLE.

    This Act may be cited as the ``Childhood Cancer Survivorship, 
Treatment, Access, and Research Reauthorization Act of 2022'' or the 
``Childhood Cancer STAR Reauthorization Act''.
SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.

    (a) Children's Cancer Biorepositories.--Section 417E of the Public 
Health Service Act (42 U.S.C. 285a-11) is amended--
            (1) in subsection (a)--
                    (A) in paragraph (2)(A), by inserting before the 
                period at the end of the second sentence the following: 
                ``, such as collected samples of both solid tumor cancer 
                and paired samples'';
                    (B) in paragraph (9), by striking ``Childhood Cancer 
                Survivorship, Treatment, Access, and Research Act of 
                2018'' and inserting ``Childhood Cancer Survivorship, 
                Treatment, Access, and Research Reauthorization Act of 
                2022'';
                    (C) by redesignating paragraph (10) as paragraph 
                (11); and
                    (D) by inserting after paragraph (9) the following:
            ``(10) Report on researcher access to children's cancer 
        biorepository samples.--Not later than 2 years after the date of 
        enactment of the Childhood Cancer Survivorship, Treatment, 
        Access, and Research Reauthorization Act of 2022, the Director 
        of NIH shall--
                    ``(A) <<NOTE: Review.>>  conduct a review of the 
                procedures established under paragraph (2)(C) and other 
                policies or procedures related to researcher access to 
                such biospecimens to identify any opportunities to 
                reduce administrative burden, consistent with paragraph 
                (2)(D), in a manner that protects personal privacy to 
                the extent required by applicable Federal and State 
                privacy law, at a minimum; and
                    ``(B) submit to the Committee on Health, Education, 
                Labor, and Pensions of the Senate and the Committee on 
                Energy and Commerce of the House of Representatives a 
                report on the findings of the review under subparagraph 
                (A) and whether the Director of NIH plans to make any 
                changes to the policies or procedures considered in such 
                review, based on such findings.''; and

[[Page 136 STAT. 6263]]

            (2) in subsection (d), by striking ``2019 through 2023'' and 
        inserting ``2024 through 2028''.

    (b) Cancer Survivorship Programs.--Section 201 of the Childhood 
Cancer Survivorship, Treatment, Access, and Research Act of 2018 (Public 
Law 115-180) <<NOTE: 42 USC 285a-11a note.>>  is amended--
            (1) in subsection (a)--
                    (A) in the subsection heading, by striking ``Pilot 
                Programs to Explore'' and inserting ``Research to 
                Evaluate''
                    (B) in paragraph (1)--
                          (i) by striking ``may make awards to eligible 
                      entities to establish pilot programs'' and 
                      inserting ``shall, as appropriate, make awards to 
                      eligible entities to conduct or support 
                      research'';
                          (ii) by striking ``model systems'' and 
                      inserting ``approaches'';
                          (iii) by inserting ``and adolescent'' after 
                      ``childhood''; and
                          (iv) by striking ``evaluation of models for'';
                    (C) in paragraph (2)--
                          (i) in subparagraph (A), in the matter 
                      preceding clause (i), by inserting ``within the 
                      existing peer review process,'' after 
                      ``practicable,''; and
                          (ii) in subparagraph (B)(v), by striking ``in 
                      treating survivors of childhood cancers'' and 
                      inserting ``in carrying out the activities 
                      described in paragraph (1)''; and
                    (D) in paragraph (3)(B)(v), by striking ``design of 
                systems for the effective transfer of treatment 
                information and care summaries from cancer care 
                providers to other health care providers'' and inserting 
                ``design tools to support the secure electronic transfer 
                of treatment information and care summaries between 
                health care providers or, as applicable and appropriate, 
                longitudinal childhood cancer survivorship cohorts''; 
                and
            (2) in subsection (b)--
                    (A) in each of paragraphs (1) and (2), by striking 
                ``date of enactment of this Act'' and inserting ``date 
                of enactment of the Childhood Cancer Survivorship, 
                Treatment, Access, and Research Reauthorization Act of 
                2022''; and
                    (B) in paragraph (1)--
                          (i) by striking subparagraphs (A) and (C);
                          (ii) by redesignating subparagraph (B) as 
                      subparagraph (A); and
                          (iii) by adding at the end the following:
                    ``(B) recommendations for enhancing or promoting 
                activities of the Department of Health and Human 
                Services related to workforce development for health 
                care providers

[[Page 136 STAT. 6264]]

                 who provide psychosocial care to pediatric cancer 
                patients and survivors.''.

    Approved January 5, 2023.

LEGISLATIVE HISTORY--S. 4120:
---------------------------------------------------------------------------

CONGRESSIONAL RECORD, Vol. 168 (2022):
            Dec. 20, considered and passed Senate.
            Dec. 22, considered and passed House.

                                  <all>
Childhood Cancer STAR Reauthorization Act

Sponsors

Subjects

Summary

Full Text

Legislative Actions

Ask about this bill
